What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Internal medicine, Surgery, Gastroenterology, Chemotherapy and Colorectal cancer are his primary areas of study.
The study of Internal medicine is intertwined with the study of Oncology in a number of ways.
He interconnects Clinical trial and Capecitabine in the investigation of issues within Surgery.
His studies deal with areas such as Phases of clinical research, Survival rate, Regimen, Neutropenia and Performance status as well as Gastroenterology.
His Chemotherapy research is multidisciplinary, incorporating perspectives in Toxicity, Clinical endpoint, Pancreatic cancer and Prospective cohort study.
As a part of the same scientific family, he mostly works in the field of Colorectal cancer, focusing on Chemoradiotherapy and, on occasion, Total mesorectal excision.
His most cited work include:
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. (4248 citations)
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer (3798 citations)
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial (2786 citations)
What are the main themes of his work throughout his whole career to date?
David Cunningham mainly investigates Internal medicine, Oncology, Surgery, Chemotherapy and Colorectal cancer.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His study looks at the relationship between Oncology and topics such as Gemcitabine, which overlap with Pancreatic cancer.
His research links Hazard ratio with Surgery.
His work deals with themes such as Carcinoma, Disease, Toxicity, Lymphoma and Adenocarcinoma, which intersect with Chemotherapy.
His studies in Colorectal cancer integrate themes in fields like Cancer research and Chemoradiotherapy, Radiation therapy.
He most often published in these fields:
- Internal medicine (64.19%)
- Oncology (37.99%)
- Surgery (28.39%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (64.19%)
- Oncology (37.99%)
- Colorectal cancer (26.06%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Cancer research.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Gastroenterology.
His Gastroenterology study incorporates themes from Survival rate, Gemcitabine, Fluorouracil and Performance status.
His work carried out in the field of Oncology brings together such families of science as Phases of clinical research, Randomized controlled trial, Rituximab, Biomarker and Nivolumab.
In his study, Capecitabine is inextricably linked to Surgery, which falls within the broad field of Colorectal cancer.
His Chemotherapy study also includes
- Adenocarcinoma together with Perioperative,
- Oxaliplatin that connect with fields like Regimen.
Between 2016 and 2021, his most popular works were:
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial (782 citations)
- Patient-derived organoids model treatment response of metastatic gastrointestinal cancers (482 citations)
- European evidence-based guidelines on pancreatic cystic neoplasms (333 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
David Cunningham focuses on Internal medicine, Oncology, Colorectal cancer, Surgery and Gastroenterology.
Internal medicine is represented through his Hazard ratio, Chemotherapy, Survival rate, Clinical trial and Randomized controlled trial research.
David Cunningham combines subjects such as Biomarker, Cancer, Fluorouracil and Precision medicine with his study of Oncology.
David Cunningham works mostly in the field of Colorectal cancer, limiting it down to topics relating to Immunohistochemistry and, in certain cases, Prospective cohort study.
In his study, Clinical endpoint and Liver function is strongly linked to Capecitabine, which falls under the umbrella field of Surgery.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Phases of clinical research, Carcinoma, Gemcitabine, Survival analysis and Performance status.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
